HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammati…
$0.77-3.43%
报价 2026-11-13
市值
$268,761
EV
$6.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -95.8%
$0.77$18.36
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| HCWBHCW Biologics Inc. | $268,761 | -3.4% | -86.6% | 95.9% | – | – | – | |
| BCDABioCardia, Inc. | $12.6M | +0.6% | 0.0% | 0% | – | – | – | |
| INABIN8bio, Inc. | $8.9M | -0.0% | +418.5% | 0% | – | – | – | |
| APREAprea Therapeutics, Inc. | $5.9M | -5.4% | +266.7% | 0% | – | – | – | |
| ACXPAcurx Pharmaceuticals, Inc. | $5.8M | -2.5% | -97.1% | 0% | – | – | – | |
| CELZCreative Medical Technology Holdings, Inc. | $4M | -14.4% | +779900.0% | -1,732.4% | – | – | – | |
| NRSNNeuroSense Therapeutics Ltd. | $3.2M | -4.0% | – | 0% | – | – | – | |
| RNAZTransCode Therapeutics, Inc. | $1.4M | -5.1% | -50.0% | 0% | – | – | – | |
| APVOAptevo Therapeutics Inc. | $1.3M | -10.0% | +141.9% | 0% | – | – | – | |
| 同行中位数 | – | – | +141.9% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。